Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
2020-08-24 · Ionis Pharmaceuticals · original ionis.com ↗
Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease BOSTON and CARLSBAD, Calif., Aug. 24, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx), an investigational antisense therapy being developed to treat patients with certain cardiovascular diseases, will be presented in a Late Breaking Clinical Trial Session at the upcoming ESC Congress 2020, the annual meeting of the European Society of Cardiology, which is expected to be the world's largest online gathering of cardiovascular professionals and is taking place August 29-September 1, 2020.
The release as fetched from its publisher. ionis.com ↗